Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01

Next Previous
Trial Profile

An Open Label Extension Study of HT-100 in Patients With Duchenne Muscular Dystrophy Who Have Completed Protocol HALO-DMD-01

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Halofuginone (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Adverse reactions
  • Acronyms HALO
  • Sponsors Akashi Therapeutics; Halo Therapeutics; Processa Pharmaceuticals

Most Recent Events

  • 06 Jul 2017 Status changed from suspended to discontinued as dosing stopped.
  • 03 Feb 2016 Status changed from active, no longer recruiting to suspended as dosing suspended temporarily, according to ClinicalTrials.gov record.
  • 25 Jan 2016 According to an Akashi Therapeutics media release, dosing and enrollment in this trial has been suspended based on discussions with the FDA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top